Immix Biopharma — Momentum builds with NEXICART-2 progress
Immix Biopharma’s FY25 results reflect a year in which its investment case shifted from early clinical promise to clearer regulatory progress....
141 Views
Immix Biopharma — NXC-201’s path to BLA submission
Immix Biopharma recently reported a positive clinical update for the registrational NEXICART-2 trial, evaluating lead CAR-T candidate NXC-201 in...
257 Views
Immix Biopharma — Promising NEXICART-2 data; runway extended
Immix Biopharma has presented a promising clinical update at the American Society of Hematology (ASH) 67th Annual Meeting. The interim study data...
198 Views
Immix Biopharma — Primed to pick up the pace in ALA
Immix reported its results for Q325, a period of steady progress for its lead CAR-T asset, NXC-201, in the NEXICART-2 trial for amyloid light chain...
139 Views
Immix Biopharma — NEXICART-2 enrolment progressing well
Immix Biopharma has announced that its US-based NEXICART-2 trial, evaluating lead CAR-T asset NXC-201 in amyloid light chain amyloidosis (ALA), has...
490 Views